Form D · Biotechnology
Nuvectis Pharma, Inc.
Fort Lee, NJ · CIK 0001875558
Offering snapshot reported Aug 10, 2022 · SEC filing
- Reported sold
- $15.9M Offering amount: $15.9M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 27, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 10, 2022 | Initial | $15,878,637 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.36M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-455560
A cash fee of 7% of aggregate gross proceeds of the private placement, management fee of 1% of of aggregate gross proceeds of the private placement, a non-accountable expense allowance of $85,000.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co. | 375 |
Source: Form D, filed Aug 10, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ron Bentsur | Director, Executive |
| Michael Carson | Executive |
| Kenneth Hoberman | Director |
| Matthew Kaplan | Director |
| James Oliviero | Director |
| Enrique Poradosu | Executive |
| Shay Shemesh | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Bridge Plaza Suite 275
Fort Lee, NJ, 07024
Fort Lee, NJ, 07024